Does quetiapine increase total cholesterol, LDL‑cholesterol, and triglycerides?

Does Quetiapine Increase Cholesterol?

Yes, quetiapine increases total cholesterol, LDL-cholesterol, and triglycerides, with the effect being dose-dependent and clinically significant even at low doses.

Evidence from Guidelines and FDA Labeling

The 2012 Endocrine Society Clinical Practice Guideline explicitly identifies quetiapine among second-generation antipsychotics that "can be associated with hypertriglyceridemia" 1. The guideline specifically notes that antipsychotics associated with weight gain, insulin resistance, and worsening metabolic syndrome—including quetiapine—are particularly important contributors to secondary hyperlipidemia 1.

FDA-Approved Labeling Data

The FDA prescribing information for quetiapine provides concrete evidence of lipid abnormalities 2:

In adults with schizophrenia (6-week trials):

• Total cholesterol ≥240 mg/dL: 18% on quetiapine vs 7% on placebo
• Triglycerides ≥200 mg/dL: 22% on quetiapine vs 16% on placebo

In adults with bipolar depression (8-week trials):

• Total cholesterol ≥240 mg/dL: 9% on quetiapine vs 6% on placebo
• LDL-cholesterol ≥160 mg/dL: 6% on quetiapine vs 5% on placebo
• Triglycerides ≥200 mg/dL: 14% on quetiapine vs 9% on placebo

In children and adolescents with schizophrenia:

• Total cholesterol ≥200 mg/dL: 12% on quetiapine vs 2% on placebo
• Triglycerides ≥150 mg/dL: 17% on quetiapine vs 8% on placebo
• LDL-cholesterol ≥130 mg/dL: 4% on quetiapine vs 2% on placebo

Low-Dose Quetiapine Effects

Critically, even low-dose quetiapine (≤50 mg) causes significant lipid abnormalities. The most recent high-quality evidence from a 2023 Danish nationwide study of 106,711 patients demonstrated that low-dose quetiapine initiation was associated with 3:

• Increased triglycerides (β = 1.049,95% CI: 1.027-1.072)
• Decreased HDL-cholesterol (β = 0.982,95% CI: 0.978-0.986)
• Among individuals with normal baseline values: significant increases in HbA1c, total cholesterol, and LDL-cholesterol

A 2025 meta-analysis confirmed these findings, showing that low-dose quetiapine (<200 mg) led to significant weight gain (mean difference = 0.58 kg) and HDL cholesterol reduction (mean difference = -1.25 mg/dL), with patients being 2.12 times more likely to gain ≥7% of baseline weight 4.

Comparative Risk Among Antipsychotics

Quetiapine ranks among the higher-risk antipsychotics for metabolic effects, though not the worst. The 2015 Endocrine Society guideline on obesity management notes that weight gain with quetiapine ranges from 2.3 to 6.1 kg in youth, compared to 3.8 to 16.2 kg with olanzapine 5. However, quetiapine consistently shows worse lipid profiles than risperidone or ziprasidone.

A 2009 Veterans Affairs study of 6,331 patients found that odds ratios for abnormal lipids were in the order: olanzapine > quetiapine > risperidone > haloperidol 6. Another 2009 comparative study showed quetiapine patients had significantly higher total cholesterol (194 vs 178 mg/dL, p=0.004) and triglycerides (225 vs 172 mg/dL, p<0.001) compared to other antipsychotics, with effect sizes around 0.40 7.

Clinical Implications and Monitoring

The metabolic effects of quetiapine translate to cardiovascular risk. A 2022 Danish cohort study of 60,566 low-dose quetiapine users demonstrated increased risk of major adverse cardiovascular events (adjusted HR=1.52,95% CI: 1.35-1.70) with continuous use, particularly in women and those aged ≥65 years 8.

Key Clinical Pitfalls to Avoid:

1. Don't assume low doses are metabolically safe: Even doses ≤50 mg cause significant lipid abnormalities
2. Don't overlook patients with normal baseline lipids: These patients show significant increases in total cholesterol, LDL-cholesterol, and HbA1c on quetiapine
3. The effect is dose-dependent for most parameters: Higher doses cause progressively worse metabolic effects for HbA1c, total cholesterol, LDL-cholesterol, and HDL-cholesterol (but not triglycerides, which increase even at low doses) 3

Monitoring Algorithm:

• Baseline: Obtain fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) before initiating quetiapine
• Follow-up: Repeat lipid panel at 3 months, then every 6-12 months during treatment
• Consider alternative agents (aripiprazole or ziprasidone) if lipid abnormalities develop, as these have not shown the same hypertriglyceridemic effects 1